Drug news
Takeda expands market coverage of Amitiza (lubiprostone)- Sucampo + Takeda
Sucampo Pharmaceuticals,and Takeda Pharmaceutical Company Limited have announced that on October 17, 2014, they entered into a global license, development, commercialization and supply agreement for Amitiza (lubiprostone). Through this agreement, Takeda expanded its exclusive rights beyond the United States and Canada to further develop and commercialize Amitiza in all global markets, except Japan and the People�s Republic of China.